BridgeMD
New treatment option for Overweight
Official title A Study of Eloralintide (LY3841136) in Participants With Overweight or Obesity
ClinicalTrials.gov ID: NCT07665879
What this study is testing
What is Eloralintide?
Eloralintide is an investigational medicine, given as an injection under the skin, being studied as a potential treatment for overweight.
Also referred to as LY3841136.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The main purpose of the study is to measure and compare the effects of eloralintide and placebo on insulin sensitivity (how your body responds to insulin), metabolic health (things like sugar and cholesterol), and body weight in participants with obesity or overweight. For each participant, the study will last about 35 weeks and include 3 in patient visits totaling 7 days.
- Phase 1: an early, usually small safety study
- You might receive a placebo (an inactive treatment) instead of the study drug.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 70. Healthy volunteers may be eligible.
You may be able to join if
- Have an hemoglobin A1c (HbA1c) value at screening of less than 6.5 percent (%).
- Have a body mass index between 25 and 45 Kilogram per Square Meter (kg/m²).
- Have had a stable body weight that has changed by less than 5% during the 3 months prior to screening.
- Are individuals assigned male at birth (AMAB) or assigned female at birth (AFAB). Individuals of childbearing potential (IOCBP) and individuals not...
You likely can't join if
- Have type 1 or type 2 diabetes mellitus, a history of ketoacidosis, or of hyperosmolar state or coma. Note: Participants with a history of...
- Have acute or chronic pancreatitis or a history of acute idiopathic pancreatitis.
- Have a known clinically significant gastric emptying abnormality or chronically take drugs that directly affect gastrointestinal (GI) motility to a...
- Have a prior or planned surgical treatment for obesity. Exceptions: The following are allowed if they occurred more than 1 year before screening:
- liposuction
- cryolipolysis, or
See the full eligibility criteria
- Have an hemoglobin A1c (HbA1c) value at screening of less than 6.5 percent (%).
- Have a body mass index between 25 and 45 Kilogram per Square Meter (kg/m²).
- Have had a stable body weight that has changed by less than 5% during the 3 months prior to screening.
- Are individuals assigned male at birth (AMAB) or assigned female at birth (AFAB). Individuals of childbearing potential (IOCBP) and individuals not of childbearing potential (INOCBP) may participate in this study.
- Have type 1 or type 2 diabetes mellitus, a history of ketoacidosis, or of hyperosmolar state or coma. Note: Participants with a history of gestational diabetes are eligible to participate in this study.
- Have acute or chronic pancreatitis or a history of acute idiopathic pancreatitis.
- Have a known clinically significant gastric emptying abnormality or chronically take drugs that directly affect gastrointestinal (GI) motility to a significant extent.
- Have a prior or planned surgical treatment for obesity. Exceptions: The following are allowed if they occurred more than 1 year before screening:
- liposuction
- cryolipolysis, or
- abdominoplasty.
- Are unwilling to comply with the lifestyle and dietary restrictions required for this study.
- Are individuals AFAB who are lactating.
- Are individuals AFAB who are pregnant or intend to become pregnant or to breastfeed during the study, or individuals AMAB who intend to conceive a pregnancy during the study.
The study team makes the final eligibility decision.
Where it's taking place
- Neuss, Germany
- Mölndal, Sweden
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 70 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Neuss, Germany; Mölndal, Sweden. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.